SeaStar Medical Holding (ICU) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Nov. 06, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	SEASTAR MEDICAL HOLDING CORPORATION
Entity Central Index Key	0001831868
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39927
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3681132
Entity Address, Address Line One	3513 Brighton Blvd.,
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80216
City Area Code	844
Local Phone Number	427-8100
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,463,148
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ICU
Security Exchange Name	NASDAQ
Redeemable Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share
Trading Symbol	ICUCW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash	$ 2,082	$ 176
Accounts receivable	68	0
Prepaid expenses	1,466	2,132
Total current assets	3,616	2,308
Other assets	970	1,205
Total assets	4,586	3,513
Current liabilities
Accounts payable	3,687	4,372
Accrued expenses	2,291	1,523
Contract liabilities	550	100
Notes payable, net of deferred financing costs	0	565
Convertible notes, current portion	0	4,179
Liability classified warrants	110	2,307
Total current liabilities	6,638	13,046
Notes payable, net of deferred financing costs	0	4,143
Convertible notes, net of current portion	0	194
Total liabilities	6,638	17,383
Commitments and contingencies (Note 11)
Stockholders' deficit
Preferred stock - $0.0001 par value per share; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023	0	0
Common stock - $0.0001 par value per share; 500,000,000 shares authorized; 4,214,399 and 2,016,045 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	133,092	100,863
Accumulated deficit	(135,145)	(114,734)
Total stockholders' deficit	(2,052)	(13,870)
Total liabilities, convertible preferred stock and stockholders' deficit	$ 4,586	$ 3,513

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	4,214,399	2,016,045
Common stock, shares outstanding	4,214,399	2,016,045

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net revenue	$ 68,000	$ 0	$ 68,000	$ 0
Cost of goods sold	0	0	0	0
Gross profit	68,000		68,000
Operating expenses
Research and development	2,336,000	1,087,000	6,367,000	4,798,000
General and administrative	2,188,000	1,855,000	6,776,000	6,475,000
Total operating expenses	4,524,000	2,942,000	13,143,000	11,273,000
Loss from operations	(4,456,000)	(2,942,000)	(13,075,000)	(11,273,000)
Other income (expense)
Interest income	58,000	0	82,000	0
Interest expense	(272,000)	(224,000)	(497,000)	(882,000)
Change in fair value of convertible notes	0	(291,000)	(6,145,000)	(291,000)
Change in fair value of liability classified warrants	192,000	1,025,000	(773,000)	1,784,000
Change in fair value of forward option-prepaid forward contracts	0	0	0	(1,308,000)
Loss on extinguishment of convertible notes	0	(4,949,000)	0	(4,949,000)
Other income	0	149,000	0	149,000
Total other income (expense), net	(22,000)	(4,290,000)	(7,333,000)	(5,497,000)
Loss before provision for income taxes	(4,478,000)	(7,232,000)	(20,408,000)	(16,770,000)
Provision for income taxes	0	0	3,000	5,000
Net loss	$ (4,478,000)	$ (7,232,000)	$ (20,411,000)	$ (16,775,000)
Net loss per share:
Net loss per share of common stock, basic	$ (1.1)	$ (9.02)	$ (6.1)	$ (26.16)
Net loss per share of common stock, diluted	$ (1.1)	$ (9.02)	$ (6.1)	$ (26.16)
Weighted-average shares of common stock outstanding - basic	4,086,871	801,939	3,348,490	641,125
Weighted-average shares of common stock outstanding - diluted	4,086,871	801,939	3,348,490	641,125

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ (20,762)	$ 1	$ 67,739	$ (88,502)
Beginning Balances (in shares) at Dec. 31, 2022		507,987
Issuance of shares - equity line of credit, Shares		15,120
Issuance of shares - equity line of credit	1,108		1,108
Issuance of shares - commitment fee for equity line of credit, Shares		8,754
Issuance of shares - commitment fee for equity line of credit	1,000		1,000
Issuance of shares - prepaid forward contracts (As restated)	1,870		1,870
Stock-based compensation	505		505
Net loss	(7,096)			(7,096)
Ending Balance at Mar. 31, 2023	(23,375)	$ 1	72,222	(95,598)
Ending Balances (in shares) at Mar. 31, 2023		531,861
Beginning Balance at Dec. 31, 2022	(20,762)	$ 1	67,739	(88,502)
Beginning Balances (in shares) at Dec. 31, 2022		507,987
Net loss	(16,775)
Ending Balance at Sep. 30, 2023	(16,017)	$ 1	89,259	(105,277)
Ending Balances (in shares) at Sep. 30, 2023		1,088,045
Beginning Balance at Mar. 31, 2023	(23,375)	$ 1	72,222	(95,598)
Beginning Balances (in shares) at Mar. 31, 2023		531,861
Issuance of shares - equity line of credit, Shares		1,080
Issuance of shares - equity line of credit	55		55
Issuance of shares - prepaid forward contracts, Shares		43,879
Issuance of shares - conversion of convertible notes, Shares		123,527
Issuance of shares - conversion of convertible notes	1,937		1,937
Issuance of shares - vesting of RSUs		6,136
Forward Purchase Agreement Derivative Liability	11,519		11,519
Stock-based compensation	555		555
Stock-based compensation, Shares		18,367
Net loss	(2,447)			(2,447)
Ending Balance at Jun. 30, 2023	(11,756)	$ 1	86,288	(98,045)
Ending Balances (in shares) at Jun. 30, 2023		724,850
Issuance of shares - equity line of credit, Shares		9,383
Issuance of shares - equity line of credit	120		120	0
Issuance of shares - prepaid forward contracts, Shares		1,314
Issuance of shares - conversion of convertible notes, Shares		337,301
Issuance of shares - conversion of convertible notes	2,411		2,411
Stock-based compensation	440		440
Stock-based compensation, Shares		15,197
Net loss	(7,232)			(7,232)
Ending Balance at Sep. 30, 2023	(16,017)	$ 1	89,259	(105,277)
Ending Balances (in shares) at Sep. 30, 2023		1,088,045
Beginning Balance at Dec. 31, 2023	(13,870)	$ 1	100,863	(114,734)
Beginning Balances (in shares) at Dec. 31, 2023		2,016,078
Issuance of shares - conversion of convertible notes, Shares		507,912
Issuance of shares - conversion of convertible notes	9,389		9,389
Issuance of shares - exercise of warrants, Shares		352,074
Issuance of shares - exercise of warrants	3,959		3,959
Issuance of shares - equity offerings, net of issuance costs, Shares		252,182
Issuance of shares - equity offerings, net of issuance costs	8,309		8,309
Stock-based compensation	434		434
Net loss	(12,697)			(12,697)
Ending Balance at Mar. 31, 2024	(4,476)	$ 1	122,954	(127,431)
Ending Balances (in shares) at Mar. 31, 2024		3,128,246
Beginning Balance at Dec. 31, 2023	(13,870)	$ 1	100,863	(114,734)
Beginning Balances (in shares) at Dec. 31, 2023		2,016,078
Net loss	(20,411)
Ending Balance at Sep. 30, 2024	(2,052)	$ 1	133,092	(135,145)
Ending Balances (in shares) at Sep. 30, 2024		4,214,399
Beginning Balance at Mar. 31, 2024	(4,476)	$ 1	122,954	(127,431)
Beginning Balances (in shares) at Mar. 31, 2024		3,128,246
Issuance of shares - conversion of convertible notes, Shares		92,858
Issuance of shares - conversion of convertible notes	826		826
Issuance costs - registration of previously issued warrants	(56)		(56)
Stock-based compensation	41		41
Net loss	(3,236)			(3,236)
Ending Balance at Jun. 30, 2024	(6,901)	$ 1	123,765	(130,667)
Ending Balances (in shares) at Jun. 30, 2024		3,221,104
Issuance of shares - stock issued for Board compensation in-lieu of cash, Shares		10,120
Issuance of shares - stock issued for Board compensation in-lieu of cash	210		210
Issuance of shares - vesting of RSUs		12,766
Issuance of shares - stock issued for employee bonuses, Shares		10,323
Issuance of shares - equity offerings, net of issuance costs, Shares		960,086
Issuance of shares - equity offerings, net of issuance costs	8,917		8,917
Stock-based compensation	200		200
Net loss	(4,478)			(4,478)
Ending Balance at Sep. 30, 2024	$ (2,052)	$ 1	$ 133,092	$ (135,145)
Ending Balances (in shares) at Sep. 30, 2024		4,214,399

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (4,478)		$ (7,232)	$ (20,411)	$ (16,775)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of deferred financing costs				102	37
Change in fair value of convertible notes (issued, converted and outstanding)				6,145	291
Change in fair value of forward purchase agreement derivative liability				0	1,308
Change in fair value of liability classified warrants (exercised and outstanding)	(192)		(1,025)	773	(1,784)
Stock-based compensation				675	1,544
Loss on extinguishment of convertible notes	0	$ (5,800)	4,949	0	4,949
Changes in operating assets and liabilities
Accounts receivable				(68)	0
Other receivables				0	12
Prepaid expenses				666	805
Other assets				235	0
Accounts payable				(858)	3,115
Accrued expenses				932	698
Other liabilities				495	0
Net cash used in operating activities				(11,314)	(5,800)
Cash flows from financing activities
Proceeds from issuance of convertible notes				979	6,500
Payment of convertible notes				(700)	(282)
Proceeds from issuance of shares				13,582	1,283
Proceeds from exercise of convertible note warrants				853	0
Proceeds of pre-funded warrants				3,766	0
Payment of commitment fee - equity line of credit				0	(500)
Proceeds from sale of recycled shares				0	1,870
Proceeds from notes payable				0	100
Payment of notes payable				(5,260)	(3,145)
Net cash provided by financing activities				13,220	5,826
Net increase in cash				1,906	26
Cash, beginning of period		$ 176		176	47	$ 47
Cash, end of period	$ 2,082		$ 73	2,082	73	$ 176
Supplemental disclosure of cash flow information
Cash paid for interest				523	707
Exercise of liability classified warrants				3,106	0
Shares issued as payment of convertible notes				10,210	4,348
Shares issued to settle forward option-prepaid forward contracts				0	558
Board compensation settled in shares of common stock in-lieu-of-cash				210	0
Issuance of convertible note warrants				$ 586	$ 2,705

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,478)	$ (3,236)	$ (12,697)	$ (7,232)	$ (2,447)	$ (7,096)	$ (20,411)	$ (16,775)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false	false
Non-Rule 10b5-1 Arrangement Adopted	false	false
Rule 10b5-1 Arrangement Terminated	false	false
Non-Rule 10b5-1 Arrangement Terminated	false	false

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1. D e scription of Business Organization and Description of Business SeaStar Medical Holding Corporation, a Delaware corporation ("SeaStar") and its wholly owned subsidiary, SeaStar Medical, Inc., are collectively referred to as the "Company". SeaStar Medical, Inc. was incorporated as a Delaware corporation in June 2007, and it is headquartered in Denver, Colorado. The Company is a commercial stage medical technology company developing a proprietary platform therapy, its Selective Cytopheretic Device (“SCD”), to reduce the consequences of hyperinflammation on vital organs. The initial target of this technology is for the treatment of acute kidney injuries. The Company received FDA approval for our pediatric SCD on February 22, 2024, under a Humanitarian Device Exemption ("HDE"), and shipped its first commercial units in July 2024. A pivotal clinical trial for the SCD in adult patients with Acute Kidney Injury ("AKI") is underway with 51 patients enrolled. On October 28, 2022, LMF Merger Sub, Inc., a wholly owned subsidiary of LMF Acquisition Opportunities, Inc., (“LMAO”) merged with and into SeaStar Medical, Inc. (the "Business Combination"), with SeaStar Medical, Inc. surviving the Business Combination as a wholly owned subsidiary of LMAO. Following the consummation of the Business Combination, LMAO was renamed "SeaStar Medical Holding Corporation." Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the year ended December 31, 2024, or for any future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the related notes for the year ended December 31, 2023. There have been no material changes in our significant accounting policies as described in our Annual Report on Form 10-K for the year ended December 31, 2023 except for inclusion of the (i) Company’s policy for revenue recognition, and (ii) adoption of the expected credit loss model pursuant to Topic 326 - Credit Losses , which is discussed in Note 2 of this Form 10-Q. The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company's wholly owned subsidiary, SeaStar Medical, Inc. All significant intercompany transactions have been eliminated in consolidation. On June 7, 2024, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock , par value $ 0.0001 (the "common stock"). Following the effect of the Reverse Stock Split, each 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock . All stock options and warrants of the Company outstanding immediately prior to the Reverse Stock Split were proportionally adjusted except for the Listed Warrants and the private placement warrants that were issued as part of the SPAC transaction that closed on October 28, 2022, which total 16,788,000 outstanding warrants in the aggregate (the “Unadjusted Warrants”). The Unadjusted Warrants retained an $ 11.50 exercise price each and require the exercise of 25 warrants to purchase one share of common stock. Unless otherwise indicated, all other share and per share amounts in this quarterly report reflect the effect of the Reverse Stock Split. The par value of the Company’s common stock remained unchanged at $ 0.0001 per share and the number of authorized shares of common stock remained the same after the Reverse Stock Split. Segment Information The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. Liquidity and Going Concern The Company incurred losses of $ 4.5 million and $ 20.4 million for the three- and nine-months ended September 30, 2024, respectively. As of September 30, 2024, the Company has an accumulated deficit o f $ 135.1 million and cash of $ 2.1 million . We do not believe our cash will be sufficient to enable us to fund our operations, including clinical trial expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited interim condensed consolidated financial statements. We believe that these conditions raise substantial doubt about our ability to continue as a going concern. The Company's need for additional capital will depend in part on the scope and costs of its development activities. Through September 30, 2024, the Company generated approximately $ 0.1 million in revenue as a result of the commencement of commercial sales of the Company's pediatric SCD devices during the three-months ended September 30, 2024. The Company's ability to generate sufficient product revenue to generate positive operating cash flows will depend on continued commercialization of the Company's pediatric SCD and FDA approval and commercialization of its adult SCD devices. Until such time, if ever, the Company expects to finance its operations through the sale of its pediatric SCD, equity or debt, borrowing under credit facilities, through potential collaborations, other strategic transactions or grants. Adequate capital may not be available to the Company when needed or on acceptable terms. Risks and Uncertainties The Company is subject to risks common to early-stage companies in the medical technology industry including, but not limited to, the success of its clinical trials, new medical and technological innovations, dependence on key personnel, supply of key components, protection of proprietary technology, and product liability. There can be no assurance that the Company's products or services will be accepted in the marketplace, nor can there be any assurance that any future products or services can be developed or deployed at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all. These factors could have a materially adverse effect on the Company's future financial results, financial position and cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include (i) revenue recognition, (ii) the valuation of the liability classified warrants, (iii) prepaid forward purchase agreement derivative liability, (iv) provision for income taxes, (v) convertible debt measured at fair value, and (vi) the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. Fair Value of Financial Instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statements of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to the fair value of liability classified warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants in each reporting period is recorded to the change in fair value of warrants liability in the consolidated statements of operations. Revenue Recognition Overall Under ASC Topic 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company evaluates the following criteria: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct combined performance obligation is identified. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as contract obligations. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current contract obligations. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as contract obligations, net of current portion. See Note 3 – Revenue and Contract Obligations for further details. Product Sales Revenue The Company has sold and intends to continue to sell its products either through a combination of distributor(s) and/or directly to end-user qualified customers through the Company's own internal commercial/sales resources. The acting distributor during the three- and nine-months ended September 30, 2024, subsequently resold and was to continue to resell the products to present and future customers, until such time the Company terminated its agreement with the distributor (see Notes 3, 11, and 15). • Timing of Revenue Recognition – During the brief history (commenced July 2024) of selling pediatric SCDs, revenue has been recognized based on a freight-on-board destination (" FOB Destination " ) requirement. • Chargebacks, Government Rebates and Discounts – During the brief history of selling pediatric SCDs commercially, the Company has not agreed to chargebacks, government rebates or discounts. • Returns – Returns are specific to each order, but generally the Company allows for returns of any damaged or non-conforming product within 30 days of receipt of product. Given the (i) overall rate of product shipped that is defective/damaged, (ii) overall volume of sales to individual end-user customers, (iii) expected supply in the customer channel, and (iv) expected usage by customers, the Company does not anticipate that there will be significant risk of product returns overall. • Variable Consideration – based on the above and given the materiality of current sales (less than $ 0.1 million sold through the three- and nine-months ended September 30, 2024), the Company does not currently estimate a constraint on revenue recognized on product sales. • Transaction Price – based on the above, as currently constructed, the Company's transaction price is fixed, based on the agreed-upon price per each purchase order submitted by each customer. Milestone or up-front payments unique to the distributor were disclosed in Note 3 (also see Notes 11 and 15), and are not expected to be recognized as revenue, but merely returned as a result of a settlement to cease the relationship with the distributor. • Allocation of Consideration – each sale of a pediatric SCD is independent of any and all other sales. The entire transaction price for each pediatric SCD is allocated to the sale of that pediatric SCD. The Company will continue to monitor all of the above as the Company continues to commercialize and increase its customer base, which could result with each distributor or end-user customer agreement resulting in its own unique terms and conditions, that will potentially impact the timing and amount of revenue recognition pursuant to US GAAP. Cost of Goods Sold Prior to July 2024, the Company only manufactured/assembled pediatric or adult SCDs for research oriented and/or clinical trial related activities. Accordingly, as of and during the three-and nine-months ended September 30, 2024, all inventory on-hand or utilized had $ 0 value, as it was expensed to research and development expense at the time of purchase. Accordingly, for pediatric SCDs sold during the three-and nine-months ended September 30, 2024, the Company recognized no cost of goods sold, as there was no value attributed to those units sold. As the Company procures inventory in the future, the Company will place value on raw materials and component parts,, as there is the potential that the raw materials could be used either for (i) commercial purposes ( pediatric SCD sales ) or (ii) research and development purposes ( adult SCDs used in ongoing clinical trials ). Accounts Receivable, net The need for a credit loss allowance is evaluated each reporting period based on the Company's assessment of the credit worthiness of its customers or any other potential circumstances that could result in a credit loss. The Company uses an aging schedule method for estimating expected credit losses. As the Company just commenced commercial operations during the three-months ended September 30, 2024, with a limited customer base, the Company's estimates are based on customer specific facts, until such time that the Company has developed sufficient collection history data in which to apply a portfolio-wide expected credit loss estimate based on an aging schedule. The Company believes that the entire accounts receivable balance as of September 30, 2024, is collectible and there is no reserve for a credit loss allowance provided as of September 30, 2024. Emerging Growth Company Status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Recently issued accounting standards Accounting Standards Update 2023-09 — In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures. Accounting Standards Update 2023-07 — In November 2023, the FASB issued Accounting Standards Update 2023-07 , Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This guidance improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses, and is effective for fiscal years beginning after December 15, 2023 on a retrospective basis. The Company is currently assessing the impact of this guidance on our disclosures, but does not expect adoption to have an impact on our consolidated financial statements.

Revenues and Contract Obligatio

Revenues and Contract Obligations	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenues and Contract Obligations	Note 3. Revenues and Contract Obligations In December 2022, the Company entered into a License and Distribution Agreement (the "Distribution Agreement") with Nuwellis, Inc. ("Nuwellis") granting exclusive distribution rights of the Company's pediatric SCD within the United States of America. Under the terms of the Distribution Agreement, Nuwellis would pay the Company consideration comprising both (i) a per unit sales price for each unit shipped and (ii) a royalty for all units sold to customers. In addition, Nuwellis also agreed to pay (i) a $ 100 thousand upfront payment at contract inception (the "Up-front Payment"), and (ii) two contingent milestones payments consisting of (a) $ 450 thousand payment upon meeting the regulatory milestone of receiving HDE approval from the FDA (the "Regulatory Milestone Payment"), and (b) $ 300 thousand payment upon meeting a sales-based milestone (the "Sales Based Milestone Payment"). The Company had the following performance obligations within the Distribution Agreement: (i) a material right to Nuwellis consisting of an exclusive option for Nuwellis to purchase additional pediatric SCDs during the term of the Distribution Agreement for a discounted price, (ii) to provide training to Nuwellis personnel and medical professionals at end-user customers of Nuwellis and (iii) upon each receipt of a valid Nuwellis purchase order, delivery of pediatric SCDs. The transaction price for the Nuwellis material right and training is comprised of the Upfront Payment, the Regulatory Milestone Payment and the Sales Based Milestone Payment. The transaction price for each pediatric SCD device sold was the actual price for each device and the estimated royalties to be received. As of September 30, 2024, the Company received full consideration for the Up-front Payment and the Regulatory Milestone Payment. No revenue had been recognized from this consideration as of September 30, 2024, which has been accounted for and disclosed as contract liabilities and was to be recognized over the remaining term of the Distribution Agreement beginning with the first commercial shipment to Nuwellis. The following table summarizes the changes in the Company's contract liability balance for the nine months ended September 30, 2024 and 2023: Nine Months Ended Year-Ended ($ in thousands) September 30, 2024 December 31, 2023 Contract liabilities, beginning of period $ 100 $ — Consideration received 450 100 Revenue — — Contract liabilities, end of period $ 550 $ 100 As of September 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was equal to the contract liability balance. The Company and Nuwellis entered into a confidential settlement agreement on October 20, 2024 (the "Settlement Agreement"), in connection with the Company's termination of the Distribution Agreement on August 18, 2024. Under the Settlement Agreement the Company agreed to refund Nuwellis the entire $ 550 thousand contract liability; comprised of the Upfront Payment and Regulatory Milestone; plus an additional $ 350 thousand. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information. As a result, the Company (i) was precluded from recognizing revenue of approximately $ 0.1 million for product shipments to Nuwellis during the three-months ended September 30, 2024, (ii) was precluded from recognizing any revenues related to contract liabilities arising the Upfront Payment and Regulatory Milestone through September 30, 2024, (see below), and (iii) does not anticipate there will be any future shipments of pediatric SCDs to Nuwellis going forward. Due to the termination of the Distribution Agreement and related Settlement Agreement, the Company will be unable to recognize any revenue from the Up-Front Payment or the Regulatory Milestone Payment already received. Since the termination of the Distribution Agreement, the Company developed its own commercial operations and sold approximately $ 0.1 million of pediatric SCDs to an end-user customer during the three-months ended September 30, 2024. The Company's sales during the three- and nine-months ended September 30, 2024, were all within the same reportable segment (the Company is a single reportable/operating segment due to its size and business operations). In addition, as the Company can only commercially sell pediatric SCDs within the United States of America. There are no sales to foreign jurisdictions.

Trade Accounts Receivable

Trade Accounts Receivable	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Trade Accounts Receivable	Note 4. Trade Accounts Receivable The table below presents the opening and closing balances of accounts receivable, on a gross and net basis, with the total change in expected credit losses. ($ in thousands) Accounts Receivable, Gross Expected Credit Losses Accounts Receivable, Net December 31, 2023 $ — $ — $ — Increase in trade accounts receivable, gross 68 — 68 September 30, 2024 $ 68 $ — $ 68

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Note 5. Accrued Expenses Accrued expenses consisted of the following amounts as of September 30, 2024, and December 31, 2023: ($ in thousands) As of September 30, As of December 31, Accrued bonus $ 1,184 $ 501 Accrued director compensation 296 427 Accrued research and development expenses 281 507 Accrued legal 42 43 Accrued interest — 19 Contract settlement contingent liability (*) 350 — Other 138 26 Total accrued expenses $ 2,291 $ 1,523 (*) - The Company and Nuwellis entered into the Settlement Agreement in connection with the Company's termination of the Distribution Agreement on August 18, 2024. A contingent liability of $ 350,000 was recognized in connection with the Settlement Agreement to reflect that the circumstances that gave rise to this obligation existed as of September 30, 2024. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2024
Notes Payable [Abstract]
Notes Payable	Note 6. Notes Payable Notes payable activity was as follows for the nine-month period ended September 30, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Investor D Note Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ — $ ( 52 ) Note issued in exchange for warrants — — — — $ 450 — Payments ( 296 ) ( 1,128 ) ( 2,771 ) ( 565 ) ( 450 ) ( 50 ) Amortization of costs — — — — — 102 Balance as of September 30, 2024 $ — $ — $ — $ — $ — $ — There are no future maturities of any of the above formerly existing notes payable, as further explained below. Investor D Note On June 28, 2024, the Company and Investor D agreed to exchange all of the remaining outstanding warrants held by Investor D, which were issued in connection with Investor D's convertible debt issued between March 2023 and January 2024, into a short-term note of approximately $ 0.5 million. The interest rate on the loan was 7.0 % per annum and the note was paid in full during the three-months ending September 30, 2024. Senior Secured LMFA Note Payable The company entered into a senior secured note with LMFA in September 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during the quarter ended March 31, 2024. Senior Secured LMFAO Note Payable The company entered into a senior secured note with LMFAO in October 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during the quarter ended March 31,2024. Unsecured Maxim Note Payable In October 2022, the Company entered into an unsecured promissory note with Maxim, for an aggregate principal amount of $ 4.2 million (the "Maxim Note"). The interest rate on the note was 7.0 %. As a result of the Reverse Stock Split, the approximately $ 2.6 million remaining Maxim Note balance became due within 90 days of the June 2024 Reverse Stock Split event. The Maxim Note was paid in full during the three-months ended September 30, 2024. Insurance Financing In October 2023, the Company entered into a financing arrangement with a lender to finance a portion of the annual premium of an insurance policy in the amount of $ 0.7 million. The Company paid the remaining two monthly installments of principal and interest with the last payment being made in August 2024 .

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Convertible Notes	Note 7. Convertible Notes The activity for the convertible notes is disclosed in the table below for the nine month period ended September 30, 2024. See our Annual Report on Form 10-K for the year-ended for December 31, 2023, for other details relating to the Investor D convertible notes issued prior to December 31, 2023. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 $ 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 947 ) ( 607 ) ( 2,381 ) ( 10,319 ) (Gain)/loss on reporting period remeasurement — — — — 748 — — 748 Redemption — — — — ( 700 ) — — ( 700 ) Balance as of September 30, 2024 $ — $ — $ — $ — $ — $ — $ — $ — The Company completed additional closings related to the Second Amendment to the Investor D Securities Purchase Agreement on January 12, 2024 and January 24, 2024, issuing notes in principal amounts of $ 0.3 million and $ 0.8 million, respectively, each at 7.00 % per annum (collectively the "2024 Investor D Notes"). The 2024 Investor D Notes were to mature on April 12, 2025 and April 24, 2025 , respectively. The 2024 Investor D Notes have an initial conversion price of $ 14.00 per share and were convertible into shares of the Company's common stock, beginning on the earlier of June 11, 2024 (or earlier upon mutual written agreement of the Company and the purchaser), or the date of an event of default. The Company also issued warrants to purchase up to 5,278 and 15,382 shares of common stock, respectively, with an exercise price of $ 14.00 per share, and additional warrants to purchase up to 5,278 and 15,382 shares of common stock, respectively, with an exercise price of $ 14.00 per share. On January 30, 2024, the institutional investor agreed to waive its Optional Redemption Rights and any event of default that may arise thereunder with respect to this offering and suspend the Optional Redemption Rights for a period of sixty ( 60 ) days following the closing of this offering (the “Suspension Period”), and the Company granted the institutional investor a right to redeem all or a portion of the then outstanding Conversion Amount within three (3) trading days after the Suspension Period at an amount equal to 200 % of the Conversion Amount. During the quarter-ended March 31, 2024, the institutional investor converted approximately $ 3.3 million (face value) of outstanding debt, by converting the outstanding debt into approximately $ 9.5 million of the Company's common stock. As of March 31, 2024, the Company still owed the institutional investor approximately $ 1.0 million (face value) in convertible debt, with a fair value of approximately $ 1.1 million, which as disclosed below, was ultimately either converted or redeemed by June 30, 2024. The Company incurred a loss of approximately $ 5.8 million as a result of the following: (i) $ 4.7 million loss on conversion into equity as a result of the difference between the fair value of the convertible notes being converted and the equity being delivered, (ii) $ 0.7 million loss on issuance of the Investor D convertible notes issued during the three-months ended March 31, 2024, as a result of the combination of the fair value of detachable warrants issued in conjunction to the Investor D Notes issues during the three-months ended March 31, 2024, and the excess fair value over the proceeds received for the Investor D convertible notes issues during the three-months ended March 31, 2024, and (iii) $ 0.4 million loss on the change in fair value of those Investor D convertible notes still outstanding as of March 31, 2024. Investor D April 2024 Side Letter On April 1, 2024, the Company and Investor D entered into a side letter agreement (the "April 2024 Side Letter") whereby each party agreed to suspend certain rights of Investor D for a 60-day period, extending those rights from March 30, 2024, to May 30, 2024. Those rights included a 10-day notice period for any subsequent financing and rights to review terms of such financing arrangements. Finally, Investor D waived its rights and notice of default in the event of such financings. In addition, after the end to the May 30, 2024, suspension period being reached, Investor D has the right to require the Company to redeem all or a portion of any outstanding Investor D convertible notes at 200 % of the conversion amount (the "Make-Whole Amount"). On June 5, 2024, Investor D completed the following two transactions, eliminating the remaining outstanding convertible debt: • Converted approximately $ 0.6 million of outstanding principal and $ 0.7 million of accrued interest and Make-Whole Amount , by issuing 92,858 shares of the Company's common stock, resulting in a loss of approximately $ 0.4 million, and • Redeemed the remaining $ 0.7 million of outstanding convertible debt and Make-Whole Amount, and • As of June 30, 2024, there were no remaining outstanding convertible debt instruments. There were no additional issuances of convertible debt during the three-months ended September 30, 2024.

Equity Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Equity Transactions	Note 8. Equity Transactions January 2024 Offering On January 26, 2024, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the Company issued to the investor (the "Q1 2024 SPA"), (i) in a registered direct offering, 252,182 shares of the Company’s common stock, par value $ 0.0001 per share, and pre-funded warrants to purchase 181,449 shares of Common Stock (the "Pre-Funded Warrants") with an exercise price of $ 0.0001 per share, and (ii) in a concurrent private placement, series A warrants to purchase 433,631 shares of common stock (the "Series A Common Warrants") and series B warrants to purchase 216,816 shares of common stock each with an exercise price of $ 20.76 (the "Series B Common Warrants" and together with the Series A Common Warrants, the "Investor E Warrants"). Such registered direct offering and concurrent private placement are referred to herein as the “January 2024 Offering". The Company received aggregate gross proceeds from the January 2024 Offering of approximately $ 9.0 million, before deducting fees to the Maxim Group LLC and other estimated offering expenses payable by the Company. The Investor E Warrants became exercisable on June 4, 2024 , the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants (the "Stockholder Approval Date"). The Series A Common Warrants will expire on the fifth anniversary of the Stockholder Approval Date and the Series B Common Warrants will expire on the twelve-month anniversary of the Stockholder Approval Date. The Pre-Funded Warrants will not expire and will be exercisable commencing on January 26, 2024, and at any time until all of the Pre-Funded Warrants are exercised in full. All Pre-Funded Warrants were exercised during the first quarter ended March 31, 2024. The Company paid approximately $ 0.7 million in fees to Maxim Group LLC and issued 21,682 warrants (the "PA Warrants") to purchase shares of the Company's common stock, with a fair value of approximately $ 0.3 million at issuance. The exercise price of these warrants is $ 22.83 per share and the warrants become exercisable on July 30, 2024 , expiring five years after the closing date. July 2024 Offering On July 10, 2024, the Company entered into a securities purchase agreement (the “Q3 2024 SPA”) with certain institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market: (i) 947,868 shares of the Company’s common stock, $ 0.0001 par value per share and (ii) Common Stock purchase warrants to purchase up to 947,868 shares of Common Stock (the “July 2024 Investor Warrants”) in a concurrent private placement (together the "July 2024 Offering"). The July 2024 Investor Warrants were immediately exercisable, expire five years following the issuance date and have an exercise price of $ 10.55 per share. The Company agreed to register the shares of Common Stock underlying the Common Warrants within 30 days of the date of the Purchase Agreement. The combined purchase price of each share of Common Stock and July 2024 Investor Warrant is $ 10.55 . The gross proceeds to the Company from the Offering were approximately $ 10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. On May 17, 2024, the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the Company, on a reasonable best-efforts basis, in connection with the offering. The Company paid Wainwright an aggregate cash fee equal to (i) 6.4 % and 1 % management fee of the gross proceeds of the July 2024 Offering and (ii) for certain expenses incurred by Wainwright totaling approximately $ 0.8 million. Additionally, the Company has agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to 66,351 shares of Common Stock, equal to 7.0 % of the aggregate number of Shares placed in the Offering (the “July 202 4 PA Warrants”, which combined with the July 2024 Investor Warrants are herein referred to as the "July 2024 Warrants"). The Placement Agent Warrants have a term of five years from the commencement of sales under the Offering and an exercise price of $ 13.1875 per share of Common Stock (equal to 125 % of the offering price). August 2024 At-The-Market Offering On August 20, 2024, the Company entered into an At-The-Market Offering Agreement (the “ATM Agreement”) with Wainwright as sales agent, to sell shares of its common stock, from time to time, through an “at the market offering” program under which Wainwright will act as sales agent. The sales, if any, of the Company's Common Stock made under the ATM Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company’s common stock (the "ATM"). Through September 30, 2024, the Company raised approximately $ 0.1 million utilizing the ATM, issuing 12,218 shares of the Company's Common Stock. Tumin Equity Line of Credit During the year ended December 31, 2023, the Company sold 6,500,000 shares of common stock to Tumim for proceeds of approximately $ 4.7 million as part of the Tumin Equity Line of Credit (see the Company's Annual Report on Form 10-K for the year-ended December 31, 2023, for additional information on the structure and purpose). As of December 31, 2023, approximately $ 95.3 million was available to draw. In February 2024, the Company and Tumim agreed to terminate the Equity Line of Credit.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2024
Warrants and Rights Note Disclosure [Abstract]
Warrants	Note 9. Warrants Warrants Issued in FY 2024 July 2024 Warrants As discussed in Note 7, as part of the Q3 2024 SPA, the Company issued on July 11, 2024 the following warrants to purchase the Company's common stock to certain institutional investors and the placement agent: • July 2024 Investor Warrants - warrants to purchase 947,868 shares of the Company's common stock with an exercise price of $ 10.55 , expiring July 10, 2029 . • July 2024 PA Warrants - warrants to purchase 66,351 shares of the Company's common stock, with an exercise price of $ 13.1875 , expiring July 10, 2029 . Investor E (January 2024) Warrants As discussed in Note 7, as part of the Q1 2024 SPA, the Company issued on January 26, 2024 the following warrants to purchase the Company's common stock to Investor E: • Pre-Funded Warrants - warrants to purchase 181,449 shares of common stock with an exercise price of $ 0.0001 . The Pre-Funded Warrants had no expiration date and were exercisable commencing on the date of issuance and at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants were exercised in full during the quarter ended March 31, 2024 • Series A and Series B Common Warrants - in a concurrent private placement, Series A Common Warrants to purchase 433,631 shares of Common Stock and Series B Common Warrants to purchase 216,816 shares of common stock each with an exercise price of $ 20.76 . • PA Warrants – in a concurrent private placement, PA Warrants to purchase 21,682 shares of common stock with an exercise price of $ 22.83 per share. Investor E Warrants became exercisable on June 4, 2024 , the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants. The Series A Common Warrants will expire on June 4, 2029 , and the Series B Common Warrants will expire on June 4, 2025 . Maxim Group LLC ("Maxim") acted as the placement agent in connection with the transactions pursuant to the Placement Agency Agreement, dated January 26, 2024, by and between the Company and Maxim. On January 30, 2024, Maxim received warrants to purchase 21,682 shares of common stock covering a number of shares equal to 5 % of the total number of shares of common stock sold in the Transactions. The PA Warrants became exercisable six months after the closing and will expire on January 30, 2029 . The PA Warrants are exercisable at a price equal to 110.0 % of the offering price in connection with the placement. In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity , the Company determined the Investor E and PA Warrants meet the conditions for equity classification and should be included on the consolidated balance sheet as a component of stockholders' equity (deficit). Investor D Warrants The Company, in conjunction with additional borrowing of convertible debt related to the Second Amendment to the Investor D SPA on January 12, 2024 and January 24, 2024, issued warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share, and additional warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share. All remaining Investor D Warrants issued in connection with the Investor D SPA were exchanged for an approximately $ 0.5 million short-term note payable on June 28, 2024, eliminating all remaining Investor D Warrants issued in connection with the Investor D SPA as of June 30, 2024 (see Note 5). The Investor D Warrants issued in January 2024 in connection with the Investor D SPA were determined to be liability classified. The initial fair value of the convertible note warrants was determined using a Black-Scholes option pricing model, which considers variables such as estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is five years. Subsequent changes in fair value were recognized through earnings at each reporting period end-date or settlement date. The Company had the following warrants outstanding at September 30, 2024, and December 31, 2023: As of As of Liability Classified Warrants Investor D Warrants — 254,732 Private Placement Warrants 229,520 229,520 PIPE Investor Warrants 20,000 20,000 Subtotal 249,520 504,252 Equity Classified Warrants Investor E (January 2024) Warrants 650,446 — July 2024 Warrants 1,014,219 — Placement Agent Warrants 21,682 — Public Stockholder Warrants 422,000 422,000 Legacy Warrants 1,957 1,957 Subtotal 2,110,304 423,957 Grand Total 2,359,824 928,209 The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of September 30, 2024, and December 31, 2023: As of September 30, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Private Placement Warrants 229,520 $ 287.50 3.32 PIPE Investor Warrants 20,000 $ 287.50 3.32 Equity Classified Warrants Investor E (January 2024) Warrants 650,446 $ 20.76 4.03 July 2024 Warrants (*) 1,014,219 $ 10.72 4.78 Placement Agent Warrants 21,682 $ 22.75 4.75 Public Stockholder Warrants 422,000 $ 287.50 3.32 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 1.88 As of December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Investor D Warrants 254,732 $ 12.50 4.65 Private Placement Warrants 229,520 $ 287.50 3.82 PIPE Investor Warrants 20,000 $ 287.50 3.82 Equity Classified Warrants Public Stockholder Warrants 422,000 $ 287.50 3.82 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 2.38 (*) - The July 2024 Warrants comprise both the July 2024 Investor Warrants and the July 2024 PA Warrants. Accordingly, the reported exercise price is the weighted-average exercise price. Below is the warrant activity for the nine-months ended September 30, 2024: Investor D Warrants Investor E (January 2024) Warrants July 2024 Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 254,732 — — — 229,520 20,000 422,000 1,957 Issuance 42,217 831,895 1,014,219 21,682 — — — — Exercised ( 170,625 ) ( 181,449 ) — — — — — — Forfeited / cancelled — — — — — — — — Exchanged for Investor D Note ( 126,324 ) — — — — — — — Outstanding as of September 30, 2024 - 650,446 1,014,219 21,682 229,520 20,000 422,000 1,957 During the three months ended September 30, 2024, the Company incurred a gain of approximately $ 0.2 million from the mark-to-market adjustment for all remaining liability classified warrants. During the nine months ended September 30, 2024, the Company incurred (i) a $ 1.6 million loss from exercises of certain Investor D Warrants, (ii) a gain of $ 1.3 million from the exchange of all remaining Investor D Warrants in June 2024 for an approximately $ 0.5 million short-term Investor D Note which was paid in full during the three-months ended September 30, 2024. and (iii) a loss of approximately $ 0.5 million from the periodic mark-to-market adjustments for all liability classified warrants over that period.

Stock-Based Compensation Awards

Stock-Based Compensation Awards	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Awards	Note 10. Stock-Based Compensation Awards The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ 9 $ 198 $ 121 $ 333 General and administrative 191 286 554 1,211 Total stock-based compensation $ 200 $ 484 $ 675 $ 1,544 Equity Incentive Plan - Summary 2022 Omnibus Incentive Plan The Company's Board of Directors adopted, and the shareholders approved the 2022 Omnibus Incentive Plan to provide long-term incentive for its employees and non-employee service providers. The vesting of stock options is stated in each individual grant agreement, which is generally either one or four years . Options granted expire 10 years after the date of grant. 2019 Stock Incentive Plan The Company’s Board of Directors adopted the 2019 Stock Incentive Plan on February 25, 2019, to provide long-term incentive for its employees and non-employee service providers. The Stock Incentive Plan was terminated on October 28, 2022, and no further awards were granted under such plan. Stock Options Option activity for the period ended September 30, 2024, is as follows: 2022 Omnibus Incentive Plan - Stock Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 14,045 $ 46.00 $ — 9.3 Exercised — Issued — Forfeited / cancelled ( 931 ) Outstanding at September 30, 2024 13,114 $ 46.00 $ — 8.5 Vested and exercisable as of September 30, 2024 13,114 $ — $ — 8.5 2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 9,797 $ 46.00 $ — 6.7 Exercised — Issued — Forfeited / cancelled ( 980 ) Outstanding as of September 30, 2024 8,817 $ 46.00 $ — 5.9 Vested and exercisable as of September 30, 2024 8,238 $ 46.00 $ — 5.9 Restricted Stock Units A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding as of December 31, 2023 9,361 $ 36.75 Granted 38,000 Vested ( 9,183 ) Forfeited / cancelled ( 178 ) Outstanding as of September 30, 2024 38,000 $ 17.93 2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding as of December 31, 2023 3,698 $ 200.00 Exercised — Vested ( 1,969 ) Forfeited / cancelled ( 422 ) Outstanding as of September 30, 2024 1,307 $ 200.00

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies Lease Agreements The Company is part of a membership agreement for shared office space and can cancel at any time. Rent expense was approximately $ 8 and $ 24 thousand for the three- and nine- months ended September 30, 2024 and 2023, respectively. Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. 2022 Demand Letter In connection with the Business Combination, LMAO proposed, for stockholder approval, various amendments to its Amended and Restated Certificate of Incorporation, which included among other things a proposal to increase the authorized shares of common stock. A purported stockholder sent a Stockholder Litigation Demand letter (the “Demand”) to the Board of Directors of LMAO alleging that the Delaware General Corporation Law required a separate class vote of the Class A common stockholders to increase the authorized shares of common stock. Following receipt of the Demand, the Company canceled and withdrew the proposal to increase the authorized shares of common stock. The stockholder’s counsel thereafter demanded that the Company pay counsel fees for the purported benefit conferred upon the Company’s shareholders by causing the Company to withdraw the allegedly invalid proposal to increase the authorized shares of common stock. The Company paid approximately $ 0.2 million for a legal settlement during the year ended December 31, 2023, and this matter has been closed. 2024 Securities Class Action Lawsuit On July 5, 2024, Forrest A K Wells (the “Plaintiff”), a purported stockholder of the Company, filed a putative class action complaint in the United States District Court for the State of Colorado, captioned Wells v. SeaStar Medical Holding Corporation et al, Case No. 1:24-cv-0187 (D. Colorado) (the “Class Action”). The Class Action alleges that the Company, its Chief Executive Officer and former Chief Financial Officer made or caused to be made material misstatements or omissions regarding the Company’s business and operations, allegedly culminating in the Company’s restatement of its consolidated financial statements, disclosed in a Form 8-K and filed on March 27, 2024. The Class Action asserts claims pursuant to the Securities Exchange Act of 1934, including Section 10(b), Rule 10b-5 promulgated thereunder and Section 20(a). The Class Action seeks to recover, among other remedies, compensatory damages. The Company intends to vigorously defend the action. The Company has not recognized a contingent liability for this Class Action event as it does not qualify for the recognition criteria under ASC 450 - Contingencies. Confidential Settlement Agreement On October 20, 2024, the Company entered into the Settlement Agreement with Nuwellis whereby the Company has agreed to pay Nuwellis $ 0.9 million in connection with the Company's termination of the Distribution Agreement. Of the $ 0.9 million, $ 550 thousand represented contract liabilities previously recognized (see Note 3), and $ 350 thousand of additional consideration. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 12. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: Level 1 – quoted prices in active markets for identical assets and liabilities. Level 2 – other significant observable inputs (including quoted prices for similar assets and liabilities, interest rate, credit risk, etc.). Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities). The fair value of the forward option on prepaid forward contracts, convertible notes, and the warrants liability is classified as Level 3 in the fair value hierarchy. Fair Value Measurement Hierarchy The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, by level within the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements as of September 30, 2024 ($ in thousands) (Level 1) (Level 2) (Level 3) Total Liabilities: Liability classified warrants $ — $ — $ 110 $ 110 $ — $ — $ 110 $ 110 Fair Value Measurements as of December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486 Summary of Level 3 Input Changes The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended September 30, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward ($ in thousands) Convertible Notes Liability Classified Warrants Balance as of December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle ( 700 ) — Exchange for short-term note payable — ( 450 ) Shares issued upon conversion or exercise ( 4,922 ) ( 3,106 ) Changes in fair value 748 773 Balance as of September 30, 2024 $ — $ 110 Level 3 Inputs For assets or liabilities for which the Company is required to remeasure the fair value on a recurring basis at each reporting date, generally the Company is required to disclose certain quantitative data related to the inputs used at the most recent reporting period date. However, for those assets or liabilities for which the Company has elected to take the FVO in accordance with ASC 825, Financial Instruments , then such quantitative disclosures are not required. Liability Classified Warrants The liability classified warrants as of September 30, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of September 30, 2024 and December 31, 2023. As of September 30, 2024 Expected volatility 120.00 % Equivalent term 3.08 Risk-free rate 3.58 % Dividend yield 0.00 % Stock price $ 4.26 Strike price $ 287.50 As of December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 11.00 $ 11.00 Strike price $ 12.50 $ 287.50

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes In accordance with U.S. GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The Company’s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Except as noted below, due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company has recognized an insignificant provision for certain minimum state taxes of less than $ 0.1 million as of September 30, 2024, and December 31, 2023. The Company believes its tax filing position and deductions related to tax periods subject to examination will be sustained under audit and, therefore, has no reserve for uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 14. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands except share and per share amounts) 2024 2023 2024 2023 Net loss $ ( 4,478 ) $ ( 7,232 ) $ ( 20,411 ) $ ( 16,775 ) Weighted-average shares outstanding - basic and diluted 4,086,871 801,939 3,348,490 641,125 Basic and diluted net loss per share $ ( 1.10 ) $ ( 9.02 ) $ ( 6.10 ) $ ( 26.16 ) The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of September 30, 2024 2023 Investor D warrants — 301,170 Investor E (January 2024) warrants 650,446 — July 2024 Warrants 1,014,219 — Placement Agent warrants 21,682 — Public Stockholders' warrants 422,000 414,000 Private Placement warrants 229,520 229,520 PIPE Investor warrants 20,000 28,000 Legacy warrants 1,957 2,789 Employee based options to purchase common stock 21,352 15,933 Unvested employee based restricted stock units 39,307 12,572 Total 2,420,483 1,003,984

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events Confidential Settlement Agreement In December 2022, the Company entered into the Distribution Agreement with Nuwellis, pursuant to which the Company appointed Nuwellis as its exclusive distributor for the sale and distribution of its pediatric SCD product throughout the United States. In May 2024, the Company provided notice to Nuwellis that Nuwellis had breached the Distribution Agreement and that the Distribution Agreement would terminate effective August 18, 2024. Nuwellis disputed the validity of the termination and on October 20, 2024, the Company entered into a confidential settlement agreement and release with Nuwellis, pursuant to which the Company agreed to pay Nuwellis an aggregate of $ 900 thousand, payable in three installments through December 31, 2024. The Company paid the first installment of $ 500 thousand on October 22, 2024. At-The-Market Offering Subsequent to September 30, 2024 and as of November 11, 2024, the Company raised approximately $2.0 million by issuing approximately 0.6 million shares of the Company's common stock for net proceeds of approximately $ 1.9 million under the Company's At-the-Market offering facility which was registered on August 21, 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Use of Estimates	Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include (i) revenue recognition, (ii) the valuation of the liability classified warrants, (iii) prepaid forward purchase agreement derivative liability, (iv) provision for income taxes, (v) convertible debt measured at fair value, and (vi) the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statements of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to the fair value of liability classified warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants in each reporting period is recorded to the change in fair value of warrants liability in the consolidated statements of operations.
Revenue Recognition	Revenue Recognition Overall Under ASC Topic 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company evaluates the following criteria: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct combined performance obligation is identified. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as contract obligations. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current contract obligations. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as contract obligations, net of current portion. See Note 3 – Revenue and Contract Obligations for further details. Product Sales Revenue The Company has sold and intends to continue to sell its products either through a combination of distributor(s) and/or directly to end-user qualified customers through the Company's own internal commercial/sales resources. The acting distributor during the three- and nine-months ended September 30, 2024, subsequently resold and was to continue to resell the products to present and future customers, until such time the Company terminated its agreement with the distributor (see Notes 3, 11, and 15). • Timing of Revenue Recognition – During the brief history (commenced July 2024) of selling pediatric SCDs, revenue has been recognized based on a freight-on-board destination (" FOB Destination " ) requirement. • Chargebacks, Government Rebates and Discounts – During the brief history of selling pediatric SCDs commercially, the Company has not agreed to chargebacks, government rebates or discounts. • Returns – Returns are specific to each order, but generally the Company allows for returns of any damaged or non-conforming product within 30 days of receipt of product. Given the (i) overall rate of product shipped that is defective/damaged, (ii) overall volume of sales to individual end-user customers, (iii) expected supply in the customer channel, and (iv) expected usage by customers, the Company does not anticipate that there will be significant risk of product returns overall. • Variable Consideration – based on the above and given the materiality of current sales (less than $ 0.1 million sold through the three- and nine-months ended September 30, 2024), the Company does not currently estimate a constraint on revenue recognized on product sales. • Transaction Price – based on the above, as currently constructed, the Company's transaction price is fixed, based on the agreed-upon price per each purchase order submitted by each customer. Milestone or up-front payments unique to the distributor were disclosed in Note 3 (also see Notes 11 and 15), and are not expected to be recognized as revenue, but merely returned as a result of a settlement to cease the relationship with the distributor. • Allocation of Consideration – each sale of a pediatric SCD is independent of any and all other sales. The entire transaction price for each pediatric SCD is allocated to the sale of that pediatric SCD. The Company will continue to monitor all of the above as the Company continues to commercialize and increase its customer base, which could result with each distributor or end-user customer agreement resulting in its own unique terms and conditions, that will potentially impact the timing and amount of revenue recognition pursuant to US GAAP.
Cost of Goods Sold	Cost of Goods Sold Prior to July 2024, the Company only manufactured/assembled pediatric or adult SCDs for research oriented and/or clinical trial related activities. Accordingly, as of and during the three-and nine-months ended September 30, 2024, all inventory on-hand or utilized had $ 0 value, as it was expensed to research and development expense at the time of purchase. Accordingly, for pediatric SCDs sold during the three-and nine-months ended September 30, 2024, the Company recognized no cost of goods sold, as there was no value attributed to those units sold. As the Company procures inventory in the future, the Company will place value on raw materials and component parts,, as there is the potential that the raw materials could be used either for (i) commercial purposes ( pediatric SCD sales ) or (ii) research and development purposes ( adult SCDs used in ongoing clinical trials ).
Accounts Receivable, net	Accounts Receivable, net The need for a credit loss allowance is evaluated each reporting period based on the Company's assessment of the credit worthiness of its customers or any other potential circumstances that could result in a credit loss. The Company uses an aging schedule method for estimating expected credit losses. As the Company just commenced commercial operations during the three-months ended September 30, 2024, with a limited customer base, the Company's estimates are based on customer specific facts, until such time that the Company has developed sufficient collection history data in which to apply a portfolio-wide expected credit loss estimate based on an aging schedule. The Company believes that the entire accounts receivable balance as of September 30, 2024, is collectible and there is no reserve for a credit loss allowance provided as of September 30, 2024.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
Recently issued accounting standards	Recently issued accounting standards Accounting Standards Update 2023-09 — In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures. Accounting Standards Update 2023-07 — In November 2023, the FASB issued Accounting Standards Update 2023-07 , Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This guidance improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses, and is effective for fiscal years beginning after December 15, 2023 on a retrospective basis. The Company is currently assessing the impact of this guidance on our disclosures, but does not expect adoption to have an impact on our consolidated financial statements.

Revenues and Contract Obligat_2

Revenues and Contract Obligations (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Summary of Changes in Contract Liability	The following table summarizes the changes in the Company's contract liability balance for the nine months ended September 30, 2024 and 2023: Nine Months Ended Year-Ended ($ in thousands) September 30, 2024 December 31, 2023 Contract liabilities, beginning of period $ 100 $ — Consideration received 450 100 Revenue — — Contract liabilities, end of period $ 550 $ 100

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Schedule of Accounts Receivable, on Gross and Net Basis, with Change in Expected Credit Losses	The table below presents the opening and closing balances of accounts receivable, on a gross and net basis, with the total change in expected credit losses. ($ in thousands) Accounts Receivable, Gross Expected Credit Losses Accounts Receivable, Net December 31, 2023 $ — $ — $ — Increase in trade accounts receivable, gross 68 — 68 September 30, 2024 $ 68 $ — $ 68

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Accrued Liabilities, Current [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following amounts as of September 30, 2024, and December 31, 2023: ($ in thousands) As of September 30, As of December 31, Accrued bonus $ 1,184 $ 501 Accrued director compensation 296 427 Accrued research and development expenses 281 507 Accrued legal 42 43 Accrued interest — 19 Contract settlement contingent liability (*) 350 — Other 138 26 Total accrued expenses $ 2,291 $ 1,523 (*) - The Company and Nuwellis entered into the Settlement Agreement in connection with the Company's termination of the Distribution Agreement on August 18, 2024. A contingent liability of $ 350,000 was recognized in connection with the Settlement Agreement to reflect that the circumstances that gave rise to this obligation existed as of September 30, 2024. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information.

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Payable [Abstract]
Summary of Notes Payable	Notes payable activity was as follows for the nine-month period ended September 30, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Investor D Note Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ — $ ( 52 ) Note issued in exchange for warrants — — — — $ 450 — Payments ( 296 ) ( 1,128 ) ( 2,771 ) ( 565 ) ( 450 ) ( 50 ) Amortization of costs — — — — — 102 Balance as of September 30, 2024 $ — $ — $ — $ — $ — $ —

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Instrument [Line Items]
The Activity for the Convertible Notes	The activity for the convertible notes is disclosed in the table below for the nine month period ended September 30, 2024. See our Annual Report on Form 10-K for the year-ended for December 31, 2023, for other details relating to the Investor D convertible notes issued prior to December 31, 2023. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 $ 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 947 ) ( 607 ) ( 2,381 ) ( 10,319 ) (Gain)/loss on reporting period remeasurement — — — — 748 — — 748 Redemption — — — — ( 700 ) — — ( 700 ) Balance as of September 30, 2024 $ — $ — $ — $ — $ — $ — $ — $ —

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrants Outstanding	The Company had the following warrants outstanding at September 30, 2024, and December 31, 2023: As of As of Liability Classified Warrants Investor D Warrants — 254,732 Private Placement Warrants 229,520 229,520 PIPE Investor Warrants 20,000 20,000 Subtotal 249,520 504,252 Equity Classified Warrants Investor E (January 2024) Warrants 650,446 — July 2024 Warrants 1,014,219 — Placement Agent Warrants 21,682 — Public Stockholder Warrants 422,000 422,000 Legacy Warrants 1,957 1,957 Subtotal 2,110,304 423,957 Grand Total 2,359,824 928,209
Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche	The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of September 30, 2024, and December 31, 2023: As of September 30, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Private Placement Warrants 229,520 $ 287.50 3.32 PIPE Investor Warrants 20,000 $ 287.50 3.32 Equity Classified Warrants Investor E (January 2024) Warrants 650,446 $ 20.76 4.03 July 2024 Warrants (*) 1,014,219 $ 10.72 4.78 Placement Agent Warrants 21,682 $ 22.75 4.75 Public Stockholder Warrants 422,000 $ 287.50 3.32 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 1.88 As of December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Investor D Warrants 254,732 $ 12.50 4.65 Private Placement Warrants 229,520 $ 287.50 3.82 PIPE Investor Warrants 20,000 $ 287.50 3.82 Equity Classified Warrants Public Stockholder Warrants 422,000 $ 287.50 3.82 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 2.38 (*) - The July 2024 Warrants comprise both the July 2024 Investor Warrants and the July 2024 PA Warrants. Accordingly, the reported exercise price is the weighted-average exercise price.
Schedule of Warrant Activity	Below is the warrant activity for the nine-months ended September 30, 2024: Investor D Warrants Investor E (January 2024) Warrants July 2024 Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 254,732 — — — 229,520 20,000 422,000 1,957 Issuance 42,217 831,895 1,014,219 21,682 — — — — Exercised ( 170,625 ) ( 181,449 ) — — — — — — Forfeited / cancelled — — — — — — — — Exchanged for Investor D Note ( 126,324 ) — — — — — — — Outstanding as of September 30, 2024 - 650,446 1,014,219 21,682 229,520 20,000 422,000 1,957

Stock-Based Compensation Awar_2

Stock-Based Compensation Awards (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-based Compensation Expense	The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ 9 $ 198 $ 121 $ 333 General and administrative 191 286 554 1,211 Total stock-based compensation $ 200 $ 484 $ 675 $ 1,544
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2022 Omnibus Incentive Plan - Stock Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 14,045 $ 46.00 $ — 9.3 Exercised — Issued — Forfeited / cancelled ( 931 ) Outstanding at September 30, 2024 13,114 $ 46.00 $ — 8.5 Vested and exercisable as of September 30, 2024 13,114 $ — $ — 8.5
Summary of RSU Activity	A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding as of December 31, 2023 9,361 $ 36.75 Granted 38,000 Vested ( 9,183 ) Forfeited / cancelled ( 178 ) Outstanding as of September 30, 2024 38,000 $ 17.93
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 9,797 $ 46.00 $ — 6.7 Exercised — Issued — Forfeited / cancelled ( 980 ) Outstanding as of September 30, 2024 8,817 $ 46.00 $ — 5.9 Vested and exercisable as of September 30, 2024 8,238 $ 46.00 $ — 5.9
Summary of RSU Activity	2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding as of December 31, 2023 3,698 $ 200.00 Exercised — Vested ( 1,969 ) Forfeited / cancelled ( 422 ) Outstanding as of September 30, 2024 1,307 $ 200.00

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, by level within the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements as of September 30, 2024 ($ in thousands) (Level 1) (Level 2) (Level 3) Total Liabilities: Liability classified warrants $ — $ — $ 110 $ 110 $ — $ — $ 110 $ 110 Fair Value Measurements as of December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486
Summary of Changes in Forward Option and Convertible Notes Derivative Liability	The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended September 30, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward ($ in thousands) Convertible Notes Liability Classified Warrants Balance as of December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle ( 700 ) — Exchange for short-term note payable — ( 450 ) Shares issued upon conversion or exercise ( 4,922 ) ( 3,106 ) Changes in fair value 748 773 Balance as of September 30, 2024 $ — $ 110
Schedule of Significant Assumptions Valuing of Fair Value	The liability classified warrants as of September 30, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of September 30, 2024 and December 31, 2023. As of September 30, 2024 Expected volatility 120.00 % Equivalent term 3.08 Risk-free rate 3.58 % Dividend yield 0.00 % Stock price $ 4.26 Strike price $ 287.50 As of December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 11.00 $ 11.00 Strike price $ 12.50 $ 287.50

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Shares	The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of September 30, 2024 2023 Investor D warrants — 301,170 Investor E (January 2024) warrants 650,446 — July 2024 Warrants 1,014,219 — Placement Agent warrants 21,682 — Public Stockholders' warrants 422,000 414,000 Private Placement warrants 229,520 229,520 PIPE Investor warrants 20,000 28,000 Legacy warrants 1,957 2,789 Employee based options to purchase common stock 21,352 15,933 Unvested employee based restricted stock units 39,307 12,572 Total 2,420,483 1,003,984
Summary of Weighted Average Shares Outstanding for Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands except share and per share amounts) 2024 2023 2024 2023 Net loss $ ( 4,478 ) $ ( 7,232 ) $ ( 20,411 ) $ ( 16,775 ) Weighted-average shares outstanding - basic and diluted 4,086,871 801,939 3,348,490 641,125 Basic and diluted net loss per share $ ( 1.10 ) $ ( 9.02 ) $ ( 6.10 ) $ ( 26.16 )

Description of Business - Addit

Description of Business - Additional Information (Details) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 07, 2024 $ / shares shares	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Patient $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) $ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of enrolled patients | Patient				51
Accumulated deficit		$ 135,145		$ 135,145		$ 114,734
Cash		$ 2,082		$ 2,082		$ 176
Reverse stock split, description				On June 7, 2024, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock, par value $0.0001 (the "common stock"). Following the effect of the Reverse Stock Split, each 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock
Common stock, par value | $ / shares		$ 0.0001		$ 0.0001		$ 0.0001
Outstanding warrants | shares	16,788,000
Net revenue		$ 68	$ 0	$ 68	$ 0
Warrant exercise price | $ / shares	$ 11.5
Net loss		$ (4,478)	$ (7,232)	$ (20,411)	$ (16,775)
Conversion ratio	0.04

Summary of significant accoun_3

Summary of significant accounting policies - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Significant Accounting Policies [Line Items]
Inventory on-hand	$ 0		$ 0
Inventory utilized	0		0
Cost of goods sold	0	$ 0	0	$ 0
Reserve for credit loss allowance	0		0
Maximum [Member]
Significant Accounting Policies [Line Items]
Materiality of current sales	$ 100,000		$ 100,000

Revenues and Contract Obligat_3

Revenues and Contract Obligations - Summary of Changes in the Contract Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Contract liabilities, beginning of period	$ 100
Consideration received	450	$ 100
Contract liabilities, end of period	$ 550	$ 100

Revenues and Contract Obligat_4

Revenues and Contract Obligations - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2022	Oct. 20, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Contract liabilities	$ 550	$ 550			$ 100
Sale of Pediatric Scds	$ 100
License and Distribution Agreement [Member] | Nuwellis, Inc [Member]
Disaggregation of Revenue [Line Items]
Proceeds from upfront payment			$ 100
License and Distribution Agreement [Member] | Nuwellis, Inc [Member] | Sales Based Milestone [Member]
Disaggregation of Revenue [Line Items]
Proceeds from milestone payment			300
License and Distribution Agreement [Member] | Nuwellis, Inc [Member] | Regulatory Milestone [Member]
Disaggregation of Revenue [Line Items]
Proceeds from milestone payment			$ 450
Settlement Agreement [Member] | Nuwellis, Inc [Member]
Disaggregation of Revenue [Line Items]
Precluded revenue from product shipments		$ 100
Settlement Agreement [Member] | Nuwellis, Inc [Member] | Subsequent Event [Member]
Disaggregation of Revenue [Line Items]
Pay back for outstanding contract liabilities				$ 350
Contract liabilities				$ 550

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued bonus		$ 1,184	$ 501
Accrued director compensation		296	427
Accrued research and development expenses		281	507
Accrued legal		42	43
Accrued interest		0	19
Contract settlement contingent liability	[1]	350	0
Other		138	26
Total accrued expenses		$ 2,291	$ 1,523
[1] The Company and Nuwellis entered into the Settlement Agreement in connection with the Company's termination of the Distribution Agreement on August 18, 2024. A contingent liability of $ 350,000 was recognized in connection with the Settlement Agreement to reflect that the circumstances that gave rise to this obligation existed as of September 30, 2024. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information.

Accrued Expenses - Summary of_2

Accrued Expenses - Summary of Accrued Expenses (Parenthetical) (Details) - USD ($)		Sep. 30, 2024	Dec. 31, 2023
Accrued Expenses [Line Items]
Contract settlement contingent liability	[1]	$ 350,000	$ 0
License and Distribution Agreement [Member] | Nuwellis, Inc [Member]
Accrued Expenses [Line Items]
Contract settlement contingent liability		$ 350,000
[1] The Company and Nuwellis entered into the Settlement Agreement in connection with the Company's termination of the Distribution Agreement on August 18, 2024. A contingent liability of $ 350,000 was recognized in connection with the Settlement Agreement to reflect that the circumstances that gave rise to this obligation existed as of September 30, 2024. See Note 15 to our unaudited consolidated financial statements for the three- and nine- months ended September 30, 2024, included elsewhere in this Form 10-Q for additional information.

Trade Accounts Receivable - Sch

Trade Accounts Receivable - Schedule of Accounts Receivable, on Gross and Net Basis, with Change in Expected Credit Loss (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Increase in trade accounts receivable, gross	$ 68
Increase in trade accounts receivable, net	68
Accounts Receivable, Gross	68
Accounts Receivable, Net	$ 68	$ 0

Notes Payable - Summary of Note

Notes Payable - Summary of Notes payable (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Notes Payable [Line Items]
Payments	$ (5,260)	$ (3,145)
Amortization of costs	102	$ 37
LMFA [Member]
Notes Payable [Line Items]
Notes payable, Balance	296
Payments	(296)
LMFAO [Member]
Notes Payable [Line Items]
Notes payable, Balance	1,128
Payments	(1,128)
Maxim [Member]
Notes Payable [Line Items]
Notes payable, Balance	2,771
Payments	(2,771)
Insurance Financing [Member]
Notes Payable [Line Items]
Notes payable, Balance	565
Payments	(565)
Investor D Note [Member]
Notes Payable [Line Items]
Notes payable, Balance	0
Note issued in exchange for warrants	450
Payments	(450)
Unamortized deferred financing costs member
Notes Payable [Line Items]
Unamortized deferred financing costs, Balance	(52)
Payments	(50)
Amortization of costs	$ 102

Notes Payable - Investor D Note

Notes Payable - Investor D Note - Additional Information (Details) - Investor D Note [Member] $ in Millions	Jun. 28, 2024 USD ($)
Notes Payable [Line Items]
Short-term note	$ 0.5
Interest rate on the loan	7%

Notes Payable - Senior Secured

Notes Payable - Senior Secured LMFA Notes Payable - Additional Information (Details) - Senior Secured LMFA Notes Payable [Member]	9 Months Ended
	Sep. 30, 2024
Notes Payable [Line Items]
Debt instrument, interest rate	7%
Debt instrument, maturity date	Mar. 27, 2025

Notes Payable - Senior Secure_2

Notes Payable - Senior Secured LMFAO Note Payable - Additional Information (Details) - Senior Secured LMFAO Note Payable [Member]	9 Months Ended
	Sep. 30, 2024
Notes Payable [Line Items]
Debt instrument, maturity date	Mar. 27, 2025
Debt instrument, interest rate	7%

Notes Payable - Unsecured Maxim

Notes Payable - Unsecured Maxim Note Payable - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2024	Oct. 31, 2022	Sep. 30, 2024	Dec. 31, 2023
Notes Payable LineItems
Notes payable			$ 0	$ 565
Unsecured Maxim Note Payable [Member]
Notes Payable LineItems
Professional fees		$ 4,200
Debt instrument, interest rate		7%
Notes payable	$ 2,600
Reverse stock split maxim note due	90 days

Notes Payable - Insurance Finan

Notes Payable - Insurance Financing - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Oct. 31, 2023	Sep. 30, 2024
Notes Payable [Line Items]
Annual premium of insurance policy amount	$ 0.7
Frequency of principal and interest payments		two monthly
Payment terms		The Company paid the remaining two monthly installments of principal and interest with the last payment being made in August 2024

Convertible Notes - Activity fo

Convertible Notes - Activity for the Convertible Notes (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jun. 05, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Balance				$ 4,373
Issuance (Face Value)				1,087
Fair value of detachable warrants at issuance		$ (192)	$ (1,025)	773	$ (1,784)
(Gain)/loss on conversion				5,397
Conversion to common stock				(10,319)
(Gain)/loss on reporting period remeasurement				748
Redemption	$ (700)			(700)	$ (282)
Balance		0		0
Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				(586)
3rd Investor D Note 3-1
Debt Instrument [Line Items]
Balance				1,012
Issuance (Face Value)				0
(Gain)/loss on conversion				1,201
Conversion to common stock				(2,213)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-1 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-2
Debt Instrument [Line Items]
Balance				999
Issuance (Face Value)				0
(Gain)/loss on conversion				636
Conversion to common stock				(1,635)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-2 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-3
Debt Instrument [Line Items]
Balance				972
Issuance (Face Value)				0
(Gain)/loss on conversion				615
Conversion to common stock				(1,587)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-3 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-4
Debt Instrument [Line Items]
Balance				568
Issuance (Face Value)				0
(Gain)/loss on conversion				381
Conversion to common stock				(949)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-4 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
4th Investor D Note
Debt Instrument [Line Items]
Balance				822
Issuance (Face Value)				0
(Gain)/loss on conversion				77
Conversion to common stock				(947)
(Gain)/loss on reporting period remeasurement				748
Redemption				(700)
Balance		0		0
4th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
5th Investor D Note
Debt Instrument [Line Items]
Balance				0
Issuance (Face Value)				272
(Gain)/loss on conversion				482
Conversion to common stock				(607)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
5th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				(147)
6th Investor D Note
Debt Instrument [Line Items]
Balance				0
Issuance (Face Value)				815
(Gain)/loss on conversion				2,005
Conversion to common stock				(2,381)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		$ 0		0
6th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				$ (439)

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

Jun. 30, 2024

Jun. 05, 2024

Apr. 01, 2024

Jan. 30, 2024

Jan. 24, 2024

Jan. 12, 2024

Sep. 30, 2024

Mar. 31, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Jun. 07, 2024

Debt Instrument [Line Items]

Initial conversion price

$ 14

Warrant exercise price

$ 11.5

Loss on extinguishment of convertible notes

$ 0

$ 5,800

$ (4,949)

$ 0

$ (4,949)

Loss on coversion into equity

4,700

Debt conversion, original debt amount

$ 0

$ 0

Conversion of outstanding debt to common stock

10,319

Suspention period

60 days

Investment right notice period

10 days

Percentage Of Conversion Amount

200%

Redeemed outstanding convertible debt

$ 700

$ 700

$ 282

Investor D Convertible Notes And Warrant Activity [Member]

Debt Instrument [Line Items]

Issuing notes in principal amounts

$ 800

$ 300

Interest rate of senior unsecured convertible note issued

7%

7%

Maturity date

Apr. 24, 2025

Apr. 12, 2025

Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]

Debt Instrument [Line Items]

Issued warrants to purchase

15,382

Warrant exercise price

$ 14

$ 14

Additional warrants to purchase

15,382

Maximum [Member] | Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]

Debt Instrument [Line Items]

Issued warrants to purchase

5,278

Additional warrants to purchase

5,278

Convertible Notes [Member] | Investor Notes [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

1,000

Optional debt redemption rights suspension period

60 days

Debt redemption percentage

200%

Debt conversion, original debt amount

3,300

Conversion of outstanding debt to common stock

9,500

Fair value of convertible notes

1,100

Investor D Convertible Notes [Member]

Debt Instrument [Line Items]

Loss on issuance of the convertible notes

700

Conversion of outstanding debt to common stock

$ 400

Investor D Convertible Notes [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Loss on issuance of the convertible notes

400

Debt conversion, original debt amount

600

Debt Conversion, Accrued interest, Amount

$ 700

Debt Conversion Shares Issued

92,858

Equity Transactions - Additiona

Equity Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	9 Months Ended		12 Months Ended
	Jul. 10, 2024	May 17, 2024	Jan. 26, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 07, 2024
Class of Warrant or Right [Line Items]
Warrant exercise price								$ 11.5
Proceeds from issuance of shares					$ 13,582	$ 1,283
Amount available to draw							$ 95,300
Tumim Stone Capital [Member]
Class of Warrant or Right [Line Items]
Shares issued							6,500,000
Proceeds from issuance of shares							$ 4,700
January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price				$ 22.83	$ 22.83
Warrants to purchase Common stock			21,682
Warrants issued fair value			$ 300
Placement agent fee paid					$ 700
Warrant exerciseable date			Jun. 04, 2024		Jul. 30, 2024
July 2024 Offering [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right [Line Items]
Warrants expire		5 years
Placement agent expenses		$ 800
Percentage of placement warrant exercise price equal to offering price		125%
Percentage of warrants to purchase common stock Equal to number of shares placed in offering		7%
Aggregate cash fee percentage		6.40%
Percentage of management fee of gross proceeds		1%
August 2024 At-The-Market Offering [Member]
Class of Warrant or Right [Line Items]
Proceeds from issuance of shares				$ 100
Maximum [Member] | July 2024 Offering [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock		66,351
Common Stock [Member] | January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 0.0001
Warrants to purchase Common stock			252,182
Aggregate gross proceeds			$ 9,000
Common Stock [Member] | July 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.0001
Warrants to purchase Common stock	947,868
Aggregate gross proceeds	$ 10,000
Common Stock [Member] | August 2024 At-The-Market Offering [Member]
Class of Warrant or Right [Line Items]
Shares issued				12,218
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 20.76
Common Stock [Member] | Private Placement [Member] | January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 20.76
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			433,631
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member] | January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			433,631
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			216,816
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member] | January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			216,816
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 0.0001
Warrants to purchase Common stock			181,449
Pre-funded Warrants [Member] | Common Stock [Member] | January 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 0.0001
Warrants to purchase Common stock			181,449
Common Warrants [Member] | July 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 10.55
Warrants expire	5 years
Common warrants maturity due	30 days
Common Warrants [Member] | July 2024 Offering [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price		$ 13.1875
Common Warrants [Member] | Common Stock [Member] | July 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 10.55
Common Warrants [Member] | Common Stock [Member] | Maximum [Member] | Private Placement [Member] | July 2024 Offering [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	947,868

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended		9 Months Ended
	Jun. 28, 2024	Jan. 30, 2024	Jan. 26, 2024	Jan. 24, 2024	Jan. 12, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jul. 11, 2024	Jun. 07, 2024
Class of Warrant or Right [Line Items]
Warrants initial exercise price											$ 11.5
Fair value of detachable warrants at issuance						$ (192)	$ (1,025)	$ 773	$ (1,784)
Exchange of Outstanding warrant								10,319
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value of detachable warrants at issuance						(200)		$ 500
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price			$ 20.76
July 2024 Investor Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										947,868
Warrants initial exercise price										$ 10.55
Warrants expiry date										Jul. 10, 2029
July 2024 PA Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										66,351
Warrants initial exercise price										$ 13.1875
Warrants expiry date										Jul. 10, 2029
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			181,449
Warrants initial exercise price			$ 0.0001
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock from total shares percentage		5%
Warrants exercisable at price equal to offering price percentage								110%
Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant exerciseable date			Jun. 04, 2024
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiry date			Jun. 04, 2029
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			433,631
Series B Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants expiry date			Jun. 04, 2025
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			216,816
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants exchanged for short term notes payable	$ 500
Gain (loss) on exercises								$ (1,600)
Exchange With Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Gain (loss) on exercises						1,300
Short Term Investor D Note [Member]
Class of Warrant or Right [Line Items]
Exchange of Outstanding warrant						$ 500
Placement Agent Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock		21,682	21,682
Warrants initial exercise price			$ 22.83
Warrants expiry date		Jan. 30, 2029
Investor D Convertible Notes And Warrant Activity [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price				$ 0.56	$ 0.56
Investor D Convertible Notes And Warrant Activity [Member] | Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Issued warrants to purchase				395,781	131,927
Warrants to purchase Common stock				395,781	131,927

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 2,359,824	$ 928,209
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	249,520	504,252
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	0	254,732
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	229,520	229,520
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	20,000	20,000
Equity Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,110,304	423,957
Equity Classified Warrants [Member] | Investor E (January 2024) Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	650,446	0
Equity Classified Warrants [Member] | July 2024 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,014,219	0
Equity Classified Warrants [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	21,682	0
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	422,000	422,000
Equity Classified Warrants [Member] | Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 1,957	$ 1,957

Warrants - Schedule of Weighted

Warrants - Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche (Details) - $ / shares	Sep. 30, 2024	Jun. 07, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrant Share Equivalents		16,788,000,000
Weighted-Average Strike Price		$ 11.5
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents			254,732
Weighted-Average Strike Price			$ 12.5
Weighted-Average Time to Expiration			4 years 7 months 24 days
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	229,520		229,520
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 25 days		3 years 9 months 25 days
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	20,000		20,000
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 25 days		3 years 9 months 25 days
Equity Classified Warrants [Member] | Investor E (January 2024) Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	650,446
Weighted-Average Strike Price	$ 20.76
Weighted-Average Time to Expiration	4 years 10 days
Equity Classified Warrants [Member] | July 2024 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	1,014,219
Weighted-Average Strike Price	$ 10.72
Weighted-Average Time to Expiration	4 years 9 months 10 days
Equity Classified Warrants [Member] | Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	21,682
Weighted-Average Strike Price	$ 22.75
Weighted-Average Time to Expiration	4 years 9 months
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	422,000		422,000
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 25 days		3 years 9 months 25 days
Equity Classified Warrants [Member] | Legacy SeaStar Inc. Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	1,957		1,957
Weighted-Average Strike Price	$ 250		$ 250
Weighted-Average Time to Expiration	1 year 10 months 17 days		2 years 4 months 17 days

Warrants - Schedule of Warrant

Warrants - Schedule of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2024 shares
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	254,732
Issuance	42,217
Exercised	(170,625)
Forfeited/cancelled	0
Exchanged for Investor D Note	(126,324)
Outstanding Balance	0
Investor E (January 2024) Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	831,895
Exercised	(181,449)
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	650,446
July 2024 Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	1,014,219
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	1,014,219
Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	21,682
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	21,682
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	229,520
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	229,520
PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	20,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	20,000
Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	422,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	422,000
Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	1,957
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	1,957

Stock-Based Compensation Awar_3

Stock-Based Compensation Awards - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 200	$ 484	$ 675	$ 1,544
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	9	198	121	333
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 191	$ 286	$ 554	$ 1,211

Stock-Based Compensation Awar_4

Stock-Based Compensation Awards - Additional Information (Details) - Key Employees and Non-Employee Service Providers [Member] - 2022 Omnibus Incentive Plan [Member]	9 Months Ended
	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options expiration period	10 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years

Stock-Based Compensation Awar_5

Stock-Based Compensation Awards - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
2022 Omnibus Incentive Plan - Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	14,045
Exercised	0
Issued	0
Forfeited / cancelled	(931)
Ending balance, Outstanding	13,114	14,045
Vested and exercisable	13,114
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 46
Ending balance, Outstanding	46	$ 46
Vested and exercisable	$ 0
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	8 years 6 months	9 years 3 months 18 days
Vested and exercisable	8 years 6 months
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	9,797
Exercised	0
Issued	0
Forfeited / cancelled	(980)
Ending balance, Outstanding	8,817	9,797
Vested and exercisable	8,238
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 46
Ending balance, Outstanding	46	$ 46
Vested and exercisable	$ 46
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	5 years 10 months 24 days	6 years 8 months 12 days
Vested and exercisable	5 years 10 months 24 days

Stock-Based Compensation Awar_6

Stock-Based Compensation Awards - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	9,361
Granted	38,000
Vested	(9,183)
Forfeited / cancelled	(178)
Ending Balance, Outstanding	38,000
Beginning Balance, Outstanding | $ / shares	$ 36.75
Ending Balance, Outstanding | $ / shares	$ 17.93
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	3,698
Exercised	0
Vested	(1,969)
Forfeited / cancelled	(422)
Ending Balance, Outstanding	1,307
Beginning Balance, Outstanding | $ / shares	$ 200
Ending Balance, Outstanding | $ / shares	$ 200

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Oct. 20, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Legal settlement in accrued expenses						$ 200
Rent expense	$ 8	$ 24	$ 8	$ 24
Contract liabilities	$ 550		$ 550			$ 100
Confidential Settlement Agreement [Member] | Subsequent Event [Member] | Nuwellis, Inc [Member]
Loss Contingencies [Line Items]
Pay back outstanding amount					$ 900
Contract liabilities					550
Additional consideration					$ 350

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 110	$ 6,486
Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		4,179
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	110	2,307
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		0
Level 1 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		0
Level 2 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	110	6,486
Level 3 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		4,179
Level 3 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 110	$ 2,307

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Forward Option and Convertible Notes Derivative Liability (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 4,373
Additions	501
Cash paid to settle	(700)
Exchange for short-term note payable	0
Shares issued upon conversion or exercise	(4,922)
Changes in fair value	748
Balance	0
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,307
Additions	586
Cash paid to settle	0
Exchange for short-term note payable	(450)
Shares issued upon conversion or exercise	(3,106)
Changes in fair value	773
Balance	$ 110

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Significant Assumptions Valuing of Fair Value (Details) - Warrants [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Expected Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	120
Expected Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		90
Expected Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		85
Equivalent Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	3 years 29 days
Equivalent Term [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term		4 years 7 months 24 days
Equivalent Term [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term		4 years 14 days
Risk-Free Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	3.58
Risk-Free Rate [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		3.9
Risk-Free Rate [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		3.84
Dividend Yield [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0
Dividend Yield [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0
Dividend Yield [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0
Stock Price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	4.26
Stock Price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		11
Stock Price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		11
Strike price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	287.5
Strike price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		287.5
Strike price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		12.5

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Maximum [Member]
Schedule of Income Taxes [Line Items]
Provision for certain minimum state taxes	$ 0.1	$ 0.1

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share Basic And Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net loss	$ (4,478)	$ (3,236)	$ (12,697)	$ (7,232)	$ (2,447)	$ (7,096)	$ (20,411)	$ (16,775)
Weighted-average shares of common stock outstanding - basic	4,086,871			801,939			3,348,490	641,125
Basic net loss per share	$ (1.1)			$ (9.02)			$ (6.1)	$ (26.16)
Weighted-average shares of common stock outstanding - diluted	4,086,871			801,939			3,348,490	641,125
Diluted net loss per share	$ (1.1)			$ (9.02)			$ (6.1)	$ (26.16)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Weighted-Average Outstanding Shares (Detail) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,420,483	1,003,984
Investor D Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	301,170
Investor E (January 2024) Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	650,446	0
July 2024 Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,014,219	0
Placement Agent warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,682	0
Public Stockholders Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	422,000	414,000
Private Placement Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	229,520	229,520
PIPE Investor Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,000	28,000
Legacy (Pre-merger) Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,957	2,789
Employee Based Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,352	15,933
Unvested Employee Based Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	39,307	12,572

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands, shares in Millions			9 Months Ended
	Nov. 06, 2024	Oct. 20, 2024	Sep. 30, 2024	Sep. 30, 2023
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 13,582	$ 1,283
Subsequent Event [Member] | Confidential Settlement Agreement [Member] | Nuwellis, Inc [Member]
Subsequent Event [Line Items]
Pay back outstanding amount		$ 900
Payment of outstanding contract liabilities		500
Pay back for outstanding contract liabilities		$ 350
Subsequent Event [Member] | At-the-Market Offering [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Shares issued	0.6
Proceeds from issuance of common stock	$ 1,900